Updated: August 12, 2007
Name	ASONEP™ [Systemic formulation of humanized Sphingomab™]	iSONEP™ [Ocular formulation of humanized Sphingomab™]	Lpathomab™ [Systemic formulation]	Lpathomab™ [Ocular formulation]	T.B.D.
Target	S1P [systemically]	S1P [in the eye]	LPA [systemically]	LPA [in the eye]	Numerous bioactive-lipid targets
Primary Indications	Cancer, Fibrosis, Inflammation	AMD, Diabetic Retinopathy, Glaucoma, Others	Cancer, Pain Management	AMD	Most likely: Cancer, Inflammation, Others
Clinical Status	Late 2007	Early 2008	Late 2008 or early 2009	Late 2008 or early 2009	2009/2010 and beyond